Penumbra Reports Strong Q4 and Full Year 2025 Results Amidst Pending Boston Scientific Acquisition

summarizeSummary

Penumbra, Inc. announced robust financial results for the fourth quarter and full year 2025, with significant revenue and net income growth, while confirming no 2026 guidance due to its pending acquisition by Boston Scientific.

check_boxKey Events

• Strong Q4 2025 Performance

  Revenue increased 22.1% to $385.4 million for the fourth quarter of 2025, with net income rising to $47.3 million compared to $33.7 million in the prior year quarter.

• Solid Full Year 2025 Growth

  Full year revenue reached $1.40 billion, up 17.5% from 2024, and net income significantly improved to $177.7 million compared to $14.0 million in the prior year.

• No 2026 Financial Guidance

  The company will not provide future financial guidance or host a conference call to discuss results due to the proposed acquisition by Boston Scientific Corporation.

• Acquisition Context

  These results represent the last full annual report before the expected completion of the acquisition by Boston Scientific, which was announced in January 2026.

auto_awesomeAnalysis

Penumbra's strong financial performance for Q4 and full year 2025, marked by double-digit revenue growth and a substantial increase in net income, provides a positive backdrop as the company approaches its acquisition by Boston Scientific. The decision to withhold 2026 financial guidance and cancel the earnings call is a direct consequence of the pending merger, signaling the company's transition. Investors should view these results as a final look at Penumbra's standalone operational health and growth trajectory before the integration into Boston Scientific.